Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Biotech’s trade secrets face growing threat from foreign influences, science leaders warn

    June 8, 2023

    Canadian biotech narrows trial population to lift solid tumor drug out of FDA hold

    June 7, 2023

    Biotechs face challenges as the industry’s annual bash returns to Boston

    June 5, 2023
    Facebook Twitter Instagram
    Your Biotech
    • Bio Technology

      Biotech’s trade secrets face growing threat from foreign influences, science leaders warn

      June 8, 2023

      Canadian biotech narrows trial population to lift solid tumor drug out of FDA hold

      June 7, 2023

      Biotechs face challenges as the industry’s annual bash returns to Boston

      June 5, 2023

      The Biotech Buying Bonanza: Why The FTC’s Amgen Battle Won’t Chill The Spree

      June 5, 2023

      China reaching for biotech breakthroughs in space

      June 2, 2023
    • Pharmaceutical

      Pharma company owner duped of ₹1.1 crore

      November 11, 2022

      Novavax cuts full-year revenue forecast again amid weak demand

      November 10, 2022

      Aurobindo units recall products in US market for manufacturing issues

      November 9, 2022

      AASLD 2022 | Ascentage Pharma Releases Phase I Results of IAP Antagonist APG-1387 in an Oral Report Showing Potential for Functionally Curing CHB

      November 8, 2022

      Trade Spotlight | What should you do with Amara Raja, Sun Pharma Advanced Research, Poly Medicure on Monday?

      November 7, 2022
    Your Biotech
    Home»Bio Technology»Analysis: Biotech IPOs to bloom with a spotlight on startups with human trial data
    Bio Technology

    Analysis: Biotech IPOs to bloom with a spotlight on startups with human trial data

    yourbiotechBy yourbiotechFebruary 14, 2023Updated:February 14, 2023No Comments4 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp VKontakte Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Initial public offerings by small private biotech companies are poised to stage a comeback later in 2023 as the pace of interest rate hikes slows, but tougher economic conditions will make investors more inclined to pick firms that have drugs in human trials. Globally, IPOs across all sectors nosedived last year after a blockbuster 2021, as aggressive interest rate hikes by central banks to curb inflation put an end to the era of cheap money.

    However, more biotech companies are expected to tap the U.S. IPO market this year as the Federal Reserve dials down the size of its rate hikes and private investment rounds fail to raise adequate capital to fund expensive clinical trials, industry experts told Reuters. Still, companies that have not yet tested their drugs on humans may find it hard to attract equity investors’ attention given tighter financial conditions and a slew of disappointments from preclinical companies that went public during the IPO boom of 2021.

    “The pattern of the past few years has been to come to the market with almost anything, no matter how substantial the validation,” said David Pinniger, fund manager of the Biotech fund at Polar Capital. In these more discerning days, the weight of clinical evidence is probably going to have to be that much greater,” Pinniger added.

    Several preclinical-stage biotechs that went public in 2021 are now trading well below their IPO price, including Sana Biotechnology (SANA.O), Tenaya Therapeutics (TNYA.O), and Virpax Pharmaceuticals (VRPX.O) Along with challenging macro conditions, a string of disappointing clinical data and a dearth of large acquisitions had also sapped investor interest in the biotech sector in the first half of 2022, hammering company valuations. Small drug developers without any approved products on the market were forced to cut costs by dropping some drug study programs and implementing layoffs as funding dried up.

    Sentiment started to rebound late in 2022 and has continued into this year, with the SPDR S&P Biotech ETF, considered a yardstick for the performance of small-cap biotech firms, having risen about 3% so far this year after posting its biggest annual loss last year. While the XBI is still trading 50% below its February 2021 closing high, analysts believe the downturn in biotech has bottomed out. They also believe the outlook for the rest of the year is much brighter given the likelihood of multi-billion dollar acquisitions and innovations such as genome editing and targeted cancer drug developments.

    Biopharma companies held more than $1.4 trillion in dealmaking capacity at the beginning of December 2022, according to a report by EY, with pharmaceutical giants facing patent expiries for their key drugs on the hunt for new promising assets. There was this dam holding back all this capital,” said Sean Sun, portfolio manager at Thornburg Investment Management. Now we’re in this sweet spot where you’re seeing signs of disinflation, you’re seeing risk appetite improve. All we need is one or two biotech IPOs to get good interest and the floodgates will open.”

    Analysts have pointed to developmental obesity treatments, Alzheimer’s disease drugs, cell and gene therapies, and the breakthrough messenger-RNA technology among areas attracting investor interest. The second half of 2023 is more likely to see a significant step-up in biotech IPOs instead of the first half, as markets await further clarity on potential rate cuts,

    Along with robust clinical data, investors will be looking for companies with management teams that are capable of steering them to success after their stock market listings. A silver lining in the biotech downturn is that companies realize that they’re not necessarily entitled to great valuations because they have some interesting science,” SMBC Nikko Securities America analyst David Hoang said. The way private companies are messaging their story and thinking about pushing their pipelines forward has improved compared to the last two years,

    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Previous ArticleHow one biotech investor is changing his calculus now that Medicare can negotiate drug prices
    Next Article VJ Group backs biotech startup CrisprBits
    yourbiotech
    • Website

    Related Posts

    Biotech’s trade secrets face growing threat from foreign influences, science leaders warn

    June 8, 2023

    Canadian biotech narrows trial population to lift solid tumor drug out of FDA hold

    June 7, 2023

    Biotechs face challenges as the industry’s annual bash returns to Boston

    June 5, 2023

    The Biotech Buying Bonanza: Why The FTC’s Amgen Battle Won’t Chill The Spree

    June 5, 2023

    Leave A Reply Cancel Reply

    Our Picks

    Subscribe to Updates

    Get the latest creative news from SmartMag about art & design.

    About Us
    About Us

    We provide a wide range of customized, integrated B2B and B2C digital marketing services solutions that are ideal for your business.

    We're accepting new partnerships right now.

    Email Us: info@yourmartech.com
    Contact: +1-530-518-1420

    Our Brands
    • Your Martech
    • Your HR Tech
    • Your Fin Tech
    • Your Revenue
    • Your Info Tech
    • Your POS Tech
    • Your Health Tech
    SUBSCRIBE NOW
    Loading
    LinkedIn
    • Privacy Policy
    © 2022 Vigarbiz Inc. Designed by Vigarbiz Media

    Type above and press Enter to search. Press Esc to cancel.